Inflammatory Bowel Diseases 2003 – From Genetics to Biological Therapy

Publisher： Karger

E-ISSN： 1421-9875|21|2|83-84

ISSN： 0257-2753

Source： Digestive Diseases, Vol.21, Iss.2, 2003-10, pp. : 83-84

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre

By  

Digestive Diseases, Vol. 35, Iss. 1-2, 2017-02 ,pp. : 91-100

Karger

Access to resources Recommend Favorite

Genetics of Inflammatory Bowel Diseases – Past, Present, and Future

By  

Digestive Diseases, Vol. 21, Iss. 2, 2003-10 ,pp. : 85-90

Karger

Access to resources Recommend Favorite

Emerging Biological Treatments in Inflammatory Bowel Diseases

By  

Digestive Diseases, Vol. 24, Iss. 1-2, 2006-05 ,pp. : 131-136

Karger

Access to resources Recommend Favorite

Mycobacteria and Inflammatory Bowel Diseases: A Cumulative Association Due to Immunosuppressive Therapy?

By Molnár T.   Gyulai C.   Nagy F.   Lonovics J.  

Scandinavian Journal of Gastroenterology, Vol. 37, Iss. 9, 2002-09 ,pp. : 1114-1114

Informa Healthcare

Access to resources Recommend Favorite

Chemokines in Inflammatory Bowel Diseases

By  

Digestive Diseases, Vol. 28, Iss. 3, 2010-09 ,pp. : 386-394

Karger

Access to resources Recommend Favorite